Paion AG
PA8
Company Profile
Business description
Paion AG is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.
Contact
Heussstrasse 25
Aachen52078
DEUT: +49 24144530
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
64
Stocks News & Analysis
stocks
Moated ASX player’s future growth prospects look solid
We expect the strong earnings momentum at this company to continue, with shares looking fairly valued.
stocks
Ask the analyst: Can this genius product create the next ASX software king?
SiteMinder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,030.90 | 39.90 | -0.44% |
| CAC 40 | 7,849.96 | 62.98 | 0.81% |
| DAX 40 | 23,585.48 | 226.30 | 0.97% |
| Dow JONES (US) | 46,018.32 | 260.42 | 0.57% |
| FTSE 100 | 9,220.74 | 12.37 | 0.13% |
| HKSE | 26,544.85 | 363.54 | -1.35% |
| NASDAQ | 22,261.33 | 72.63 | -0.33% |
| Nikkei 225 | 45,303.43 | 513.05 | 1.15% |
| NZX 50 Index | 13,120.03 | 108.35 | -0.82% |
| S&P 500 | 6,600.35 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,745.20 | 47.70 | -0.54% |
| SSE Composite Index | 3,831.66 | 44.68 | -1.15% |